Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Reports summarize breast cancer research from Shanghai Jiao Tong University
December 18th, 2008
According to a study from Shanghai, People's Republic of China, " Surrogate markers may be used to assess the response to neoadjuvant treatment. The association between HER2 overexpression and favorable response to specific therapy in breast cancer is controversial, and the mechanism unclear." "The purpose of the study was to evaluate HER2 and topoisomerase II alpha (Topo II alpha) as candidates for predicting the response to neoadjuvant chemotherapy in breast cancer patients. Between 1999 and 2006, seventy-six breast cancer patients who had received neoadjuvant chemotherapy were studied. Regimens including either CEF (cyclophosphamide, epirubicin, 5-fluorouracil) or...
Source: Women's Health Weekly (2008-12-18)
|
